GAIN THERAPEUTICS, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
GAIN THERAPEUTICS, INC (GANX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.23% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-03-27
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.38%.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.23%, a 21.20% increase from fiscal 2023.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.49%, a 2.95% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.39%, a 245.92% increase from fiscal 2021.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.98%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 4.23% 10-K · filed 2025-03-27 | |||
| 2023-12-31 | 3.49% 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 3.49% 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 3.49% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 3.38% 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | 3.39% 10-K · filed 2024-03-26 | |||
| 2022-09-30 | 3.38% 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 3.14% 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | 0.98% 10-K · filed 2023-03-23 | |||
| 2021-09-30 | 0.59% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 0.31% 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |